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High-fat dietThe hallmark of NAFLD is steatosis of unknown etiology. We tested the effect of a high-protein (HP)2 diet on
diet-induced steatosis in male C57BL/6 mice with and without pre-existing fatty liver. Mice were fed all
combinations of semisynthetic low-fat (LF) or high-fat (HF) and low-protein (LP) or HP diets for 3 weeks.
To control for reduced energy intake by HF/HP-fed mice, a pair-fed HF/LP group was included. Reversibility
of pre-existing steatosis was investigated by sequentially feeding HF/LP and HF/HP diets. HP-containing
diets decreased hepatic lipids to ~40% of corresponding LP-containing diets, were more efﬁcient in this
respect than reducing energy intake to 80%, and reversed pre-existing diet-induced steatosis. Compared
to LP-containing diets, mice fed HP-containing diets showed increased mitochondrial oxidative capacity
(elevated Pgc1α, mAco, and Cpt1 mRNAs, complex-V protein, and decreased plasma free and short-chain
acyl-carnitines, and [C0]/[C16+C18] carnitine ratio); increased gluconeogenesis and pyruvate cycling
(increased PCK1 protein and fed plasma–glucose concentration without increased G6pase mRNA); reduced
fatty-acid desaturation (decreased Scd1 expression and [C16:1n−7]/[C16:0] ratio) and increased long-chain
PUFA elongation; a selective increase in plasma branched-chain amino acids; a decrease in cell stress
(reduced phosphorylated eIF2α, and Fgf21 and Chop expression); and a trend toward less inﬂammation
(lowerMcp1 and Cd11b expression and less phosphorylated NFκB). Conclusion: HP diets prevent and reverse
steatosis independently of fat and carbohydrate intake more efﬁciently than a 20% reduction in energy intake.
The effect appears to result from fuel-generated, highly distributed small, synergistic increases in lipid and
BCAA catabolism, and a decrease in cell stress.
© 2013 Elsevier B.V. All rights reserved.Embryology, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands. Tel.: +31 43 3881191; fax: +31
.nl (S.C. Garcia-Caraballo), comhair@igbmc.fr (T.M. Comhair), f.verheyen@maastrichtuniversity.nl (F. Verheyen),
a.nl (F.G. Schaap), s.m.houten@amc.uva.nl (S.M. Houten), t.hakvoort@amc.uva.nl (T.B.M. Hakvoort), chc.dejong@mumc.nl
.H. Lamers), leo.koehler@maastrichtuniversity.nl (S.E. Koehler).
Acox: acyl-coenzyme A oxidase; Akt: thymoma viral proto-oncogene 1 (a.k.a. PKB-protein kinase B); Alas1: aminolevulinic
on receptor nuclear translocator-like protein; BCAA: branched-chain amino acids; BHB: β-hydroxybutyrate; ITGAM:
DNA damage-inducible transcript 3 protein; Chrebp: carbohydrate-responsive element-binding protein; Cpt1: carnitine
IF2α: eukaryotic translation–initiation factor 2α; Elovl: elongation of very long-chain fatty acids; en%: energy percent;
f21: ﬁbroblast growth factor 21; FFA: free fatty acids; G6Pase: glucose-6-phosphatase; GCN2: general control nonrepressed
cted; HP: high protein; LF: low fat; LP: low protein; Mcp1: monocyte chemotactic protein 1; Mlxipl (a.k.a. Chrebp):
nitase; mmBCFA: monomethyl branched-chain fatty acid; NAFLD: non-alcoholic fatty liver disease; NASH: non-alcoholic
lated protein; NFκB: nuclear factor κB; Nr1d1 (a.k.a. rev-erbα): nuclear receptor subfamily 1, group D, member 1; PCK1:
inase RNA-like endoplasmic reticulum kinase; Pgc1α: pparγ-coactivator1-α, PL: choline-containing phospholipids; Ppar:
an correlation coefﬁcient; Scd1: stearoyl-CoA desaturase 1; Srebf: sterol regulatory element-binding transcription factor;
rights reserved.
686 S.C. Garcia-Caraballo et al. / Biochimica et Biophysica Acta 1832 (2013) 685–6951. Introduction
Non-alcoholic fatty-liver disease (NAFLD), the most common
chronic liver disease in afﬂuent societies, is the hepatic manifestation
of the metabolic syndrome [1]. The hallmark of NAFLD is hepatic
lipid accumulation (steatosis) of unknown etiology. Non-alcoholic
steatohepatitis (NASH) develops when a fatty liver becomes invaded
by inﬂammatory cells. Although steatosis itself is generally considered
to be benign, lipotoxic by-products of fatty-acid metabolism, such as
free fatty acids, (lyso-)phosphatidic acids, lysophosphatidylcholines,
ceramides and diacylglycerols, also accumulate [2,3]. Furthermore,
steatosis co-occurs with increased plasma insulin and VLDL, and de-
creased plasma adiponectin levels, but not necessarily with higher
body-mass index or visceral adiposity [4]. Finally, steatosis is an
established risk factor for patients undergoing major liver surgery
[5]. Steatosis-reducing therapies should beneﬁt patients with NAFLD
but, apart from changes in life style, currently no nutritional recom-
mendations or speciﬁc treatment options for NAFLD or NASH [6] exist.
Steatosis results from an imbalance between lipid supply (uptake
or de novo lipogenesis) and lipid disposal (via free fatty-acid oxida-
tion or triglyceride-rich lipoprotein secretion). Since high-protein
(HP) diets may have anti-lipogenic effects [7], we tested if a HP diet
prevents the development of steatosis in mice. Mice were fed all
four combinations of a low-fat (LF) or a high-fat (HF) and a low-
protein (LP) or a high-protein (HP) diet. Our ﬁndings show that HP-
containing diets decrease hepatic lipid content independently of die-
tary fat and carbohydrate intake, due to increased fatty-acid oxidation
and gluconeogenesis, and reduction of cellular stress. We also tested
and conﬁrmed that a HP diet can reverse a pre-existing fatty liver.
2. Methods
Detailed protocols (mRNA quantitation, Western blotting, plasma
and liver analysis) and details on materials, antibodies, diets, and
primers used (Appendix A: Supplemental Tables A.1–A.4, respectively),
andRNAnormalization (Supplemental Table A.5) are provided in online
Supplemental materials, Appendix A.
2.1. Animals
Eight-10 male C57BL/6J mice (12 weeks) were kept in groups of 2
per cage in a temperature-controlled facility with ﬁxed 12 h light–
dark cycles and free access to food andwater. Twiceweekly, food intake
and body weight were measured. After three weeks on the speciﬁed
diet, mice were sacriﬁced in the morning (10:00 h–12:30 h) to avoid
chronobiological effects. The study was approved by the Committee
for Animal Care and Use of Maastricht University.Table 1
Biometric data of WT mice fed a LF/LP, LF/HP, HF/LP, HF/HP, HF/LPres, HF/LP4w, or HF/LP→
LF/LP LF/HP HF/LP
Body weight start [g] 24.7±0.3 24.1±0.7 24.7±0.6
Weight change [% BW start] 4.0±1.2a 1.8±1.5b 6.2±2.3c⁎
Epididymal fat pad [g] 0.36±0.02a 0.31±0.02a 0.50±0.05b⁎
Liver weight [% BW] 5.4±0.1ab 5.6±0.1a 5.0±0.1b⁎
Energy intake [kcal/cage/day] 12.5±0.1a 12.3±0.9a 14.1±0.2b⁎
Reversion experiment:
Body weight start [g]
Weight change [% BW start]
Epididymal fat pad [g]
Liver weight [% BW]
Mean±SEM; n=8–10 mice per group. Different letters (a, b, or c) above the bars indica
compared to HF/LPres; # indicates Pb0.05 when HF/LP4w versus HF/LP→HP.2.2. Diets
Four semi-synthetic diets (Research Diets, New Brunswick, NJ,
USA; Supplemental Table A.3) were designed to test the effect of a
high-protein (HP) content in a low-fat (LF) or high-fat (HF) diet.
The low-protein (LP) diet contained 11 en% protein, which meets
the daily protein requirement of adult mice [8]. The LF/LP diet
contained 8 en% fat and 11 en% protein; the LF/HP diet 8 en% fat
and 35 en% protein; the HF/LP diet 42 en% fat and 11 en% protein;
and the HF/HP diet 42 en% fat and 35 en% protein. We previously
showed that the source of dietary fat does not affect the development
of fatty liver in C57BL/6 mice [9]. To control for the reduced energy
intake of mice on a HF/HP diet (~80% of that of mice on the HF/LP
diet; Table 1), an additional group (HF/LP restricted or “HF/LPres”) re-
ceived the same (reduced) amount of calories as consumed by the HF/
HP group. To determine if a HP diet also reduced the fat content of a
pre-existing steatotic liver, 12 mice were fed a HF/LP diet for three
weeks and then either the same diet (“HF/LP4w”; n=6) or a HF/HP
diet (“HF/LP→HP”; n=6) during the 4th week.
2.3. Statistical analysis
Error bars represent standard errors of the mean (SEM). A two-
way ANOVA (computed with SPSS 15) was used to test for differences
between the main effects (LP versus HP and LF versus HF) and their
interactions. Subsequently, pair-wise comparisons between groups
(LF/LP, LF/HP, HF/LP, HF/HP or HF/LPres diet) were performed. The
outcome of the reversion experiment (HF/LP4w versus HF/LP→HP)
was analyzed with a t-test. P valuesb0.05 were considered signiﬁcant
and b0.10 as indicating a trend. Details of the analyses are shown in
Supplemental Tables A.6–A.9.
3. Results
3.1. A HP content in the diet abolishes weight gain due to a HF diet
Biometric data of mice that were fed the respective experimental
diets for 3 weeks are summarized in Table 1. All diets were accepted
well. Triglyceride concentration in feces did not exceed 140 μg/100 g
fecal dry mass and did not differ between the diets (not shown), dem-
onstrating that all dietary fat was absorbed. Mice on a HP diet gained
less body weight (P=0.016) and had smaller epididymal fat pads
(P=0.006) than mice on the corresponding LP diet, but liver weight
had not changed. Mice on the HF/LP diet had a higher energy intake
(+20%) than mice on the HF/HP diet (P=0.001). If the HF/LP group
was pair-fed to the HF/HP group (HF/LPres), mice lost 3.6% of their
initial body weight (P=0.107), and had lower epididymal fat-padsHP diet.
ANOVA (P value)
HF/HP HF/LPres HP HF HPxHF
25.4±0.5 25.1±0.5 n.s. n.s. n.s.
−0.7±1.3d⁎ −3.6±2.1 0.016 n.s. 0.1
0.36±0.03a⁎ 0.39±0.04 0.006 b0.001 n.s.
5.1±0.1ab⁎ 4.5±0.1 n.s. b0.001 n.s.
11.7±0.1a 11.8±0.0 0.001 n.s. b0.001
HF/LP4w HF/LP→HP
26.9±0.7 26.8±0.6
9.2±2.9 2.3±1.8#
0.74±0.1 0.56±0.04#
4.9±0.1 5.0±0.3
te a signiﬁcant difference between the diets fed ad libitum. ⁎ indicates Pb0.05 when
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fed ad libitum.
3.2. A HP content in the diet prevents hepatic lipid accumulation
The HF/LP diet effectively induced hepatic steatosis, as demon-
strated by Oil-Red O staining (Fig. 1A) and an ~1.8-fold increase of
hepatic triglyceride (TG) concentration relative to the LF/LP diet
(Pb0.001; Fig. 1B). In mice on HP diets, hepatic fat amounted to
only 35–40% of that in mice fed with LP diets, irrespective of the fat
intake (see also Supplemental Fig. B.1). HP-containing diets had a
comparable lowering effect onhepatic free fatty acid (FFA), total choles-
terol (TC) and phospholipid (PL) concentrations (Pb0.001; Fig. 1B),
again irrespective of the fat intake. In fact, at the same dietary fat or car-
bohydrate intake, the hepatic lipid content was ~3-fold lower on diets
with a HP than a LP content (Supplemental Fig. B.1), showing that the
anti-steatotic effect of dietary protein was independent of dietary car-
bohydrate and lipid content. Concentrations of hepatic TG, FFA and TC
were similar in mice in the HF/LPres and the HF/LP groups, and higher
than in the HF/HP-fed mice (all P≤0.017; Fig. 1), despite the same
energy intake.
The HP-containing diets decreased the hepatic content of all satu-
rated C14–C22 fatty acids to a similar degree (Supplemental Table A.6).
The [C16:1n7]/[C16:0], [C18:1n9]/[C18:0], and [C16:0]/[C18:2n6] ratios in mice
on a HF diet were decreased to 35–45% of that inmice on a LF diet, indi-
cating decreased stearoyl-CoA desaturase [10] and de-novo lipogenesis
[11] activity (all Pb0.001). The protein content of the diet had no
effect. The [C18:1]/[C16:1] ratio (a measure of elongase activity [10])
was not different between the diets. The hepatic content of the essential
PUFAs linoleic (C18:2n6) andα-linolenic acids (C18:3n3) was, as expected,
higher in the HF than the LF diets, but >2-fold reduced in mice fed
theHF/HP compared to the HF/LP diet (P=0.002 and P=0.034, respec-
tively). The concentration of the functionally important PUFAs arachi-
donic acid (AA; C22:4n6), eicosapentaenoic acid (EPA; C20:5n3), andFig. 1. Hepatic lipid distribution and concentration in mice fed diets differing in protein a
(green; located pericentrally) double staining of livers from mice on the indicated diets; pa
content. The coding of the bars is shown at the bottom of the Figure. The “HF/LPres” bars in
mean±SEM, with n=8–10. Different letters (a, b, or c) above the bars indicate a signiﬁcant
between the isocaloric HF/LPres and HF/HP diets (the HF/LP and HF/LPres diets did not diffdocosahexaenoic acid (DHA; C22:6n3) was not different between
the diets, that is, preserved in mice fed the anti-steatotic HP diets
(Supplemental Fig. B.2). The [C22:4n6]/[C18:2n6] ratio, a parameter of
ELOVL5 fatty-acid elongase activity [12], was 1.3–1.6-fold increased
in mice fed a HP compared to a LP diet (P=0.004), while the
[C20:4]/[C20:3] and [C18:3n6]/[C18:2n6] ratios, reﬂecting Δ5 and Δ6
desaturase activities, respectively [10], were similar. Collectively,
these data suggest an increase in long-chain PUFA synthesis.3.3. The effects of a HP content in the diet on markers of hepatic lipid
metabolism
3.3.1. Lipogenesis
Expression of the lipogenic transcription factors Srebf1 and Mlxipl
(a.k.a. Chrebp) was not affected by the diets, but that of Pparγ was
decreased to ~50% in mice fed a HF/HP compared to a HF/LP diet
(P=0.048; Fig. 2A). The expression of fatty-acid synthase (Fasn),
stearoyl-CoA desaturase 1 (Scd1) and acetyl-CoA carboxylase-α
(Acacα) was lower in mice on a HF than a LF diet (P=0.046),
irrespective of protein intake (Fig. 2A). The HP-containing diets con-
sistently resulted in a lower mRNA abundance of these markers
than the LP-containing diets, but these differences did not reach sig-
niﬁcance. The hepatic concentration of ACACα and -β proteins was
also lower in mice fed a HF than a LF diet (P=0.011). ACACα in-
creased with an increasing dietary carbohydrate content (R2=0.64;
Pb0.001), whereas ACACβ decreased with increasing dietary fat
content (R2=0.72; Pb0.001; Fig. 2B and Supplemental Fig. B.3). The
activation status of both ACAC isoforms (P-ACAC/total ACAC; phos-
phorylation activates ACAC), and that of their kinase AMP-activated
protein kinase (AMPK) (Supplemental Fig. B.4) was not affected by
any of the diets. None of the measured genes involved in cholesterol
metabolism (Cyp7a1, Hmgcr, Srebf2) was changed in expression (Sup-
plemental Table A.7).nd fat content for 3 weeks. Panel A shows Oil-Red O (red) and glutamine synthetase
nel B, from left to right, liver triglyceride, free-fatty acid, cholesterol and phospholipid
dicate mice pair-fed the HF/LP diet to match caloric intake of HF/HP mice. Bars depict
difference between the diets fed ad libitum; * indicates a signiﬁcant difference (Pb0.05)
er in their effect on liver lipids).
Fig. 2. Differences in gene expression and metabolite concentrations in livers of mice fed diets differing in protein and fat content for 3 weeks. Panel A shows hepatic mRNA
abundance of lipogenic genes; panel B hepatic ACAC protein content (left subpanel) and phosphorylation status (right subpanel); and panel C mRNA abundance of genes involved
in fatty-acid oxidation. For bar coding, sample size and symbols, see Fig. 1.
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A HP-containing diet increased the hepatic mRNA content of the
transcription factor Pgc1α ~2.5-fold (P=0.017; Fig. 2C), and that of
Cpt1, a marker for long-chain fatty-acid transport into the mitochon-
dria, and the TCA-cycle enzyme aconitase2 (mAco) ~1.3-fold (P=
0.002). In contrast, a HF-containing diet decreasedmAcomRNA levels
to ~80% (P=0.013). The expression of other genes involved in
fatty-acid oxidation, such as Acadl, Acadm, and Acox, and Ucp2, a
marker for thermogenesis, was not signiﬁcantly affected by any of
the diets (Fig. 2C). Since mitochondria play a key role in the oxidationof fatty acids, we also measured the expression complexes I–V of
the respiratory chain, the concentration of mitochondrial DNA in
hepatocytes, and the activity of citrate synthase. Apart from complex
V protein, which was elevated by a HP diet, none of these parameters
were affected by any of the diets (Supplemental Fig. B.5). Moreover,
analysis of the ultrastructure of the hepatocyte mitochondria of
mice fed either the HF/LP or HF/HP diet revealed a very similar hepa-
tocyte make-up, except that there were fewer fat globules in the
HP-treated livers and larger, more intensely staining mitochondria
(Supplemental Fig. B.6).
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levels
Plasma glucose concentrations (Fig. 3A) were ~20% higher in
4 h-fasted mice on a HF than on a LF diet (P=0.010), but ~15% higher
in mice fed on a HP- than a LP-containing diet (P=0.025). The mRNA
levels of the catalytic subunit of glucose-6-phosphatase (G6pc) and of
phosphoenolpyruvate carboxykinase (Pck1) were similar in mice with
a LP and a HP content of the diet, but PCK1 protein content was in-
creased ~3-fold on a HP-containing diet (Pb0.001; Fig. 3B). Liver glyco-
gen concentrations were unchanged (P=0.93; Fig. 3C). As a surrogate
test for insulin sensitivity, we measured AKT phosphorylation in liver
and muscle ([13]; Supplemental Fig. B.4), but did not observe an effect
of any of the diets. As expected, the HP diets increased the mRNA levels
of the urea-cycle enzymes argininosuccinate synthetase and arginase-1
(Supplemental Table A.7).
3.5. A HP content of the diet reduces cell stress in liver
3.5.1. Endoplasmic-reticulum stress
Activation of the integrated stress response has been observed in
fatty liver [14]. The phosphorylation of the translation–initiation factor
eIF2α, a central component of this stress response, was lower in livers of
mice fed a HP- than a LP-containing diet (P=0.019; Fig. 4A), implying a
reduction of cellular stress. This effect was most pronounced in combi-
nationwith a LF diet. In line, Clec2mRNA, a target that is downregulated
upon activation of the eIF2α kinases PERK and GCN2 [15], was in-
creased in mice on a HP diet (P=0.025), while the abundance of Asns
mRNA, which is upregulated by GCN2 [15], was decreased on a HF
diet (Pb0.001). However, the protein and mRNA concentrations of the
ER-stress markers ATF4, Ddit3 (a.k.a. Chop), Gadd34 and sXbp1 were
not different (Fig. 4B, C). The validity of our cell-stress assays was con-
ﬁrmed in livers of tunicamycin-treated mice (Supplemental Fig. B.7).
The notion of a decrease in cell stress in livers of mice fed HP-
containing diets was further supported by the reduced expression of
the inﬂammatory markers Mcp1 (P=0.022) and Itgam (Cd11b; P=
0.067) (Supplemental Table A.7), and the decrease in NFκB phosphory-
lation (P=0.068; Supplemental Fig. B.4, Supplemental Table A.7).Fig. 3. Differences in glucose metabolism in mice fed diets differing in protein and fat
content for 3 weeks. Panel A shows plasma glucose levels in 4h-fasted and fed mice;
panel B depicts phosphoenolpyruvate carboxykinase (PCK1) protein and mRNA levels
of Pck1 and the catalytic subunit of glucose-6-phosphatase (G6pc). Panel C shows liver
glycogen content. For bar coding, sample size and symbols, see Fig. 1.3.5.2. Fibroblast growth factor 21
FGF21 regulates glucose, lipid, and energy homeostasis and appears
to be a marker of cell stress [16], with diet-induced obesity in mice pos-
sibly representing a FGF21-resistant state [17]. Both hepatic Fgf21
mRNA (P=0.031) and plasma FGF21 concentration (P=0.036) were
reduced in mice on a HP-containing diet (Fig. 4D), without effect of
the dietary fat content. Plasma FGF21 concentrations correlated tightly
with hepatic TG concentrations (R2=0.94; Pb0.001; Fig. 4E). Since a
HP diet induced Pgc1α and suppressed Fgf21 expression and since
PGC1α is a negative regulator of Fgf21 expression [18], we also mea-
sured the expression of other modulators of Fgf21 expression, namely
Alas1, Arnt1 (Bmal1), and Nﬁl3 (E4bp4) [18,19]. However, their mRNA
abundancewas not changed by any of the diets (Supplemental Fig. B.5).3.6. The effects of a HP content in the diet on plasma parameters of lipid
metabolism
3.6.1. Hormones and lipids
Plasma insulin, glucagon and leptin concentrations in the fed state
were not different between the groups (Table 2). A HP content of the
diet tended to increase plasma β-hydroxybutyrate (BHB) concentra-
tions (P=0.096; Table 2). Plasma FFA and TG concentrations were
not different between groups, while a HF diet increased TC concentra-
tion (P=0.039). Mice on the HF/LPres diet had unchanged plasma TG
and FFA concentrations, but a lower TC concentration compared to
mice on an ad-libitum HF diet (P=0.02).3.6.2. Acyl-carnitines
Since changes in plasma acyl-carnitines reﬂect changes in the hepatic
mitochondrial acyl-CoA pool [20], the concentration of plasma acyl-
carnitines (Fig. 5A, Supplemental Table A.8) is a parameter to assess
the balance between fatty-acid catabolism and acetyl-CoA metabolism
in the TCA cycle. The ratio between total acyl-carnitines and free carni-
tinewas similar for all diets. Inmice fed a HP-containing diet, the plasma
concentration of free carnitine and short-chain (≤C4) acyl-carnitines
was reduced to ~55% (all P≤0.013) and that of malonyl-carnitine
(C3-DC) to ~75% (P=0.014) of that in mice on a LP diet (Fig. 5A),
suggesting an enhanced fatty-acid oxidation. Plasma isovaleryl-
carnitine, a product of leucine catabolism, was the only acyl-carnitine
that was elevated in mice fed a HP diet (P=0.001). Plasma long-chain
acyl-carnitines were unaffected, except that palmitoyl-carnitine was
2-fold lower in mice fed a LF/HP than a HF/HP diet (P=0.02; Supple-
mental Table A.8). In agreement with the increased Cpt1 expression in
mice fed the HP diets (Fig. 2C), the [C0]/[C16+C18] acyl–carnitine ratio,
which correlates with carnitine palmitoyltransferase-1 activity [21],
decreased 1.4–1.8-fold (P=0.075).3.6.3. Amino acids
Despite a >3-fold increased dietary supply, the HP diets did not
change the plasma concentration of most amino acids (Supplemental
Table A.9). However, plasma branched-chain amino acids (BCAA)
were increased ~1.3-fold in mice fed a HP diet (Pb0.001; Fig. 5B)
and showed a strong inverse correlation with hepatic TG (R2=0.72;
Pb0.001) and a positive correlation with Pgc1α mRNA levels (R2=
0.55, Pb0.001; Fig. 5C, D). Because these correlations suggested a
role for BCAAs in mediating the effect of a HP diet and because the
liver is a major contributor in the irreversible step in BCAA catabolism
[22], we investigated the concentrations of their monomethyl
branched-chain fatty-acid (mmBCFA) products in liver (Supplemen-
tal Fig. B.8). Plasma leucine concentration correlated very well with
hepatic 15-methylhexanoic acid (15-MHDA) concentration (R2=
0.63, P=0.006), but the correlations of mmBCFAs with hepatic TG
contents were weak (Supplemental Fig. B.8).
Fig. 4. Expression of ER-stress markers in mice fed diets differing in protein and fat composition for 3 weeks. Panel A shows total eIF2α protein concentration and phosphorylation
(inactivation) status; panel B ATF4 protein concentration; panel C mRNA abundance of the indicated ER-stress genes; panel D hepatic Fgf21 mRNA abundance and plasma FGF21
protein concentration; panel E correlation between hepatic triglyceride concentration and plasma FGF21 concentration. For bar coding, sample size and symbols, see Fig. 1.
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To test if a HP diet could reverse pre-existing steatosis, micewere fed
a HF/LP diet for three weeks to induce a fatty liver (Fig. 1) and then
maintained on this diet for another week (“HF/LP4w”) or switched to
a HF/HP diet (“HF/LP→HP”). Mice on the HF/LP→HP regimen had
lower body and epididymal fat-pad weights than mice on the HF/LP4w
regimen (P=0.024 and 0.006, respectively, Table 1). Furthermore, this
intervention reduced hepatic TG, FFA and TC concentrations to ~40%
of that in the HF/LP4w group (Fig. 6A; all: Pb0.001; Supplemental
Fig. B.9), that is, to almost the same level as present in mice fed a HF/
HPdiet ab initio. No differences in plasma TG, FFA, or BHB concentrations
were observed, but plasma TC was ~20% lower in the HF/LP→HP than
the HF/LP4w group (Table 2; P=0.001). Markers of lipogenesis (totalACACα, Acacα, Fasn, Scd1) declined, with the reduction of AcacαmRNA
and ACAC protein concentrations reaching statistical signiﬁcance (P=
0.002 and P=0.006, respectively; Fig. 6B, C). Pgc1α mRNA was in-
creased in HF/LP→HP fed mice (P=0.001; Fig. 6D). Fasting and fed
plasma glucose concentrations were similar in both groups (Fig. 6E).
Although Pck1mRNA concentrationswere unchanged, PCK1protein con-
centration was >3-fold increased (Fig. 6E; Pb0.001). In contrast, G6pc
mRNA concentration was reduced (P=0.019, Fig. 6E). Furthermore, cell
stress markers declined: eIF2α phosphorylation was decreased to ~50%
(P=0.014; Fig. 6F) and Fgf21mRNA to ~15% (P=0.031) of the control,
while plasma FGF21 level tended to be lower (P=0.085; Fig. 6F). These
data show that the effects of increased protein content in the diet did
not dependon the previously consumeddiet andbecameeffectivewithin
one week.
Table 2
Plasma hormones and lipids of mice fed a LF/LP, LF/HP, HF/LP, HF/HP, HF/LPres, HF/LP4w, or HF/LP→HP diet.
ANOVA (P value)
LF/LP LF/HP HF/LP HF/HP HF/LPres HP HF HP×HF
Hormones
Insulin [pM] 175±23 189±58 197±48 115±19 307±48 n.s. n.s. n.s.
Leptin [pM] 239±40 200±40 316±54 235±26 345±54 n.s. n.s. n.s.
Glucagon [pM] 14±1 17±2 12±2 12±2 15±1 n.s. n.s. n.s.
Lipids
Triglyceride [mM] 0.58±0.09 0.68±0.09 0.43±0.06 0.51±0.03 0.44±0.06 n.s. n.s. n.s.
Free fatty acid [mM] 0.50±0.14 0.47±0.09 0.40±0.04 0.44±0.14 0.34±0.11 n.s. n.s. n.s.
Cholesterol [mM] 2.36±0.06 2.54±0.22 2.90±0.26 2.81±0.10 2.39±0.20 n.s. 0.039 n.s.
α-Hydroxy butyrate [mM] 0.05±0.01 0.08±0.01 0.06±0.02 0.09±0.02 0.06±0.01 0.096 n.s. n.s.
HF/LP4w HF/LP→HP
Reversion experiment
Triglyceride [mM] 0.65±0.21 0.64±0.09
Free fatty acid [mM] 0.37±0.08 0.32±0.02
Cholesterol [mM] 3.23±0.11 2.57±0.08#
α-Hydroxy butyrate [mM] 0.03±0.01 0.03±0.01
For sample size and symbols, see Table 1.
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The present study shows that a HP-containing diet effectively
reduces hepatic TG, FFA, TC, and PL concentrations and that this inter-
vention reverses a pre-existing steatosis within just one week. Thirty-
ﬁve en% protein in the diet, which is feasible and safe for humans [23],
sufﬁces to bring about this anti-steatotic effect. Of further clinical rel-
evance, a HP diet also counteracts steatosis in humans [24]. The fact
that a 3-fold increase in protein intake affected far more parameters
than a 5-fold increase in fat intake (Supplemental Table A.7, HP ver-
sus HF column) further underscores the pronounced effect of dietary
protein on hepatic metabolism.4.1. The effect of HP content of the diet on hepatic lipid balance
The hepatic content of lipids depends on the balance between
uptake plus synthesis and export plus oxidation. We observed quan-
titatively the same effects of a HP diet in APOE2ki mice that suffer
from an impeded uptake of lipids into the liver (unpublished observa-
tions), indicating that the HP effect is not mediated by a reduced fat
uptake into the liver. Very recent data indicate that inhibition of the
lipogenic marker PNPLA3 prevents fatty liver [25], but markers of li-
pogenesis, such as Fasn, Scd1, ACACα, and metabolite-based lipogenic
parameters, such as the [C16:1n7]/[C16:0] and [C16:0]/[C18:2n6] ratios
[10], were not affected by the HP diets in our study. Instead, the
lipogenic markers correlated, as expected [26], with dietary carbohy-
drate content. These data show that the inevitable decrease in dietary
carbohydrate content due to the increase in protein and/or fat con-
tent did not materially contribute to the anti-steatotic effect of HP
diets.
The capacity of the liver to oxidize fatty acids is another determinant
of the hepatic lipid balance. After three weeks on the respective diets,
none of the marker genes involved in fatty-acid oxidation (e.g. Pparα,
Acox, Acadl or Acadm) was changed in expression, but plasma acyl-
carnitine concentrations, which reﬂect changes in the hepatic mito-
chondrial acyl-CoA pool [20,21], were informative. The increase of
Cpt1 mRNA and the decrease of the plasma [C0]/[C16+C18] acyl–
carnitine ratio, which correlates with CPT1 activity [21], and the reduc-
tion in plasma free carnitine and short-chain (≤4C) acyl-carnitine
levels indicated that the import and oxidation of fatty acids into the
mitochondria increased in mice fed a HP diet. The (small) increase in
circulating ketone bodies also argued in favor of an increased hepatic
fatty-acid oxidation.Female Pparα-deﬁcient mice show no reversion of their (pre-
existing) steatosis after three weeks on a HF/HP diet, while male
Pparα-deﬁcient mice even die within 3 days on this diet [IC Gaemers
andWHLamers, unpublished observations]. This ﬁnding, which implies
a role for PPARα in the anti-steatotic effect of dietary protein, virtually
mimics the sex-dependent effects of pharmacologically blocking CPT1
activity in Pparα-deﬁcientmice [27]. Since Pparα-deﬁcientmice depend
on amino-acid catabolism for energy supply [20], carnitine availability
can apparently become a limiting factor in the oxidation of amino
acids. The increased plasma concentration of isovaleryl-carnitine, a
ﬁngerprint intermediate of BCAA catabolism, in mice fed the HP-
containing diets [28] conﬁrms that hepatic amino-acid catabolism was
increased. The hypothesis that CPT1 function is an important point of
control in the adaptation to a HP-containing diet is also supported by
the decrease in plasma malonyl-carnitine concentration of mice fed a
HP diet, becausemalonyl-CoA acts as an inhibitor of CPT1 if synthesized
via ACACβ [29]. The strongly increased hepatic PCK1-protein content,
the unchangedG6pcmRNAand hepatic glycogen levels, the higher plas-
ma glucose (in fed, but not 4h-fasted mice), and the decreased plasma
alanine concentration in mice on a HP-containing diet support an en-
hanced diversion of TCA-cycle intermediates to pyruvate cycling and
gluconeogenesis. The unchanged degree of AKT phosphorylation in
liver and muscle suggests that the HP diets did not induce insulin resis-
tance, as was observed earlier in rats [30,31].
Mitochondria play a key role in fatty-acid oxidation. The increased
expression of Pgc1α, a co-factor of PPARα and a key regulator of
mitochondrial biogenesis and the coordinated functions of the TCA
cycle and gluconeogenesis [32], may, therefore, be crucial in mediat-
ing the anti-steatotic effect of a HP diet. A HP content of the diet
also increased Pgc1α mRNA abundance in epididymal fat tissue, but
not in muscle, in agreement with the reportedly opposite effect of
PGC1α on insulin sensitivity in liver and muscle [33]. In addition to
the increase in Pgc1αmRNA, we observed an increase in the diameter
and electron density of the mitochondria (cf. [34]) and an increased
mRNA expression of aconitase, but not of other markers of mitochon-
drial biogenesis (citrate synthase, OXPHOS proteins, and mtDNA-
copy number (Supplemental Fig. B.5)). In aggregate, the data, there-
fore, suggest that increased substrate cycling in the TCA cycle arises
from a substrate supply-driven increase in enzyme activities.
The strong mutual correlations between hepatic Pgc1α mRNA
abundance, plasma BCAA, and hepatic triglyceride content suggest
a speciﬁc role for BCAA metabolism in the anti-steatotic effect of a
HP-containing diet. In support of this hypothesis, supplementation
of a diet with BCAAs, lysine, and threonine was also shown to reduce
Fig. 5. Differences in plasma metabolites in mice fed diets differing in protein and fat content for 3 weeks. Panel A shows plasma concentration of free carnitine and the indicated
acyl-carnitines; panel B plasma branched-chain amino acid (BCAA) concentration; panels C and D the correlation between plasma BCAA level and hepatic triglyceride content (TG)
and Pgc1α mRNA levels, respectively. For bar coding, sample size and symbols, see Fig. 1. Panels A-C: n=8–10 mice/group; panel D: n=6/group; panels E and F: n=6–8/group.
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had an increased plasma hydroxyvaleryl-carnitine concentration,
the high plasma BCAA levels in HP-fed mice arose from an excess sup-
ply rather than a limited catabolic capacity [36–38]. The weak corre-
lation of the lipid content of the liver with hepatic monomethyl
branched-chain fatty acids (mmBCFAs), despite the strong correlation
with plasma BCAAs, probably arises from the fact that the activity
state of branched-chain keto-acid dehydrogenase complex is much
higher in males than in females [39], so that monomethyl branched-
chain acyl-CoAs do not accumulate sufﬁciently to stimulate the synthe-
sis of mmBCFAs. In agreement, we found a strong correlation between
hepatic lipid content and mmBCFAs in female mice (Garcia-Caraballo,
unpublished results).4.2. Reduced cell stress in mice fed a HP diet
Cell stress leads to activation of stress kinases like PERK and GCN2,
which phosphorylate the translation–initiation factor eIF2α. Mice
that are deﬁcient in one of the ER stress-sensing pathways are
prone to develop steatosis in response to cell stress [40,41], which im-
plies that the capacity to cope with cell stress is necessary to avoid or
reverse steatosis. Maintaining the translation–initiation factor eIF2α
in the non-phosphorylated state is probably crucial for this effect
[40]. The decreased phosphorylation status of eIF2α in mice fed a
HP-containing diet, therefore, indicates that a HP content in the diet
resolves cell stress. The absence of a transcriptional response in the
downstream recovery pathway for cell stress (ATF4-Ddit3-Gadd34)
Fig. 6. Response to a HF/HP diet in mice with pre-existing steatosis. Panel A shows hepatic triglyceride, free fatty acid and cholesterol content; panel B hepatic ACAC protein levels
and their activation status (phosphorylation=inactivation); panel C markers of lipogenic genes; panel D Pparα and Pgc1αmRNA levels; panel E changes in glucose metabolism; and
panel F the changes in ER-stress markers. For bar coding, sample size and symbols, see Fig. 1. Panels A–C: n=8–10 mice/group; panel D: n=6/group; panels E and F: n=6–8/group.
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concurs with earlier ﬁndings that a weak activation of PERK need
not fully activate the unfolded-protein response [40,41]. The abun-
dance of Clec2 mRNA, a negatively regulated marker of PERK activity
[15], increased on a HP-containing diet, also indicating that a HP con-
tent in the diet suppressed PERK activity even in the context of a HF
diet.
One of the more striking ﬁndings was the strong positive correla-
tion between hepatic fat content and hepatic Fgf21 expression or
plasma FGF21 levels. FGF21 is also highly expressed in the liver of
obese patients [43] and rodents [17,35]. FGF21 reduces fasting blood
glucose and insulin levels, and increases, like PPARα, TCA-cycle ﬂux,
gluconeogenesis, ketogenesis and β-oxidation, and O2 consumption
[44,45] and is, in view of the increased hepatic Fgf21 mRNA abun-
dance in tunicamycin-treated mice (Supplemental Fig. B.7), probably
a marker for cell stress [16]. A strong suppression of plasma FGF21
levels was also seen upon increasing the dietary protein content
from 5.5 via 12 to 19 en% in carbohydrate-free diets [46], supporting
earlier ﬁndings that Fgf21 is also a sensitive target of GCN2 stress-
kinase activity [15,47].4.3. Conclusion
A HP-containing diet prevented and reversed hepatic steatosis
independently of dietary fat and carbohydrate intake, and was more
efﬁcient than reducing the daily energy intake to 80%. Remarkably,
this clear-cut effect could not be attributed to activation of one or a
few metabolic or signaling pathways (see Supplemental Table A.7).
The apparently highly distributed regulation of small, synergistic in-
creases in lipid and BCAA catabolism, TCA cycling and decrease in
cell stress that are induced by a HP-containing diet, together reduce
the fat content of the liver in a very effective manner. Since recent
studies have taken away concerns about the most feared side effects
of HP diets, that is, adverse effects on bone health [48,49], renal func-
tion [50], and insulin sensitivity [51], a moderately HP-containing diet
(30–40 en%) appears to be an attractive treatment option for both
short-time (e.g. to reverse steatosis prior to liver surgery [5]) and
longer-time (weight reduction [52]) dietary interventions.
Supplementary data to this article can be found online at http://
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